Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach, clinical research in cardiovascular diseases focuses on atrial fibrillation and the prevention of serious complications such as stroke.
- Evaluating new treatment options for people with atrial fibrillation who cannot use standard blood-thinning therapy
- Studying whether a novel approach can better reduce the risk of ischemic stroke and related embolic events
This work is aimed at improving both treatment effectiveness and patient safety in a high-risk heart rhythm disorder.
Digestive System Diseases
The site also conducts research in digestive system diseases, with a strong focus on ulcerative colitis and better ways to control moderate to severe inflammation.
- Comparing biological therapies to find more effective options for inducing remission in ulcerative colitis
- Assessing whether combination treatment can improve disease control compared with standard single-agent therapy
These studies are designed to support more personalized care in gastroenterology and to improve long-term outcomes for people living with chronic bowel disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Comparison of Ustekinumab, Infliximab, and Dual Biological Therapy in Moderate to Severe Ulcerative Colitis: The COMBO-UC Trial | Medical University Of Lodz | Phase II | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.